COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma

By afschroeder • August 13, 2026

Ribas A, Robert C, Schadendorf D, Long GV, Tawbi H, Flaherty K, Ascierto PA, Nathan P, Rutkowski P, Leonov OV, Lorigan P, Prey S, Saponara M, Arance A, Gaudy-Marqueste C, Stroyakovskiy D, Lebbe C, Maio M, Del Vecchio M, Boghikian PS, Gutzmer R, Depenni R, Miskic M, Russo M, Dummer R. COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma. J Clin Oncol. 2026 Aug 12:JCO2600528. doi: 10.1200/JCO-26-00528. Epub ahead of print. PMID: 42585631.

Tags: Hematology/Oncology, Publications

Biodistribution, shedding, and transmissibility of vusolimogene oderparepvec (RP1)

Wise-Draper TM, Robert C, Wong MK, Middleton MR, Sacco JJ, In GK, Muñoz Couselo E, Schadendorf D, Beasley GM, Niu J, Chmielowski B, Milhem MM,[...]

Medical Societies in the United States: History, Purpose, Challenge, and Future Directions

Schiller G, Leer LR. Medical Societies in the United States: History, Purpose, Challenge, and Future Directions. Cureus. 2026 Jul 10;18(7):e112407. doi: 10.7759/cureus.112407. PMID: 42572655; PMCID:[...]

Patient-reported outcomes in clinical trials leading to breast cancer drug approvals: are we making them count?

Margolis S, Guirguis AN, Lee C, Smith S, LeVee A, Lipsyc-Sharf MD, Bardia A, Sedrak MS. Patient-reported outcomes in clinical trials leading to breast cancer[...]